ATE324364T1 - Verwendung vom l-tartrat levalbuterolsalz in der herstellung eines dosierinhalators - Google Patents

Verwendung vom l-tartrat levalbuterolsalz in der herstellung eines dosierinhalators

Info

Publication number
ATE324364T1
ATE324364T1 AT03786896T AT03786896T ATE324364T1 AT E324364 T1 ATE324364 T1 AT E324364T1 AT 03786896 T AT03786896 T AT 03786896T AT 03786896 T AT03786896 T AT 03786896T AT E324364 T1 ATE324364 T1 AT E324364T1
Authority
AT
Austria
Prior art keywords
tartrate
production
levalbuterol
metered inhaler
salt
Prior art date
Application number
AT03786896T
Other languages
German (de)
English (en)
Inventor
Paul Mcglynn
Roger Bakale
Craig Sturge
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32507867&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE324364(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sepracor Inc filed Critical Sepracor Inc
Application granted granted Critical
Publication of ATE324364T1 publication Critical patent/ATE324364T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/56—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups
    • C07C215/58—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups with hydroxy groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
    • C07C215/60—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups with hydroxy groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain the chain having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/002—Details of inhalators; Constructional features thereof with air flow regulating means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K3/00—Materials not provided for elsewhere
    • C09K3/30—Materials not provided for elsewhere for aerosols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/04—Liquids
    • A61M2202/0468—Liquids non-physiological
    • A61M2202/0484—Alcohol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/04—Liquids
    • A61M2202/0468—Liquids non-physiological
    • A61M2202/0488—Surfactant, e.g. for the lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Materials Engineering (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Cosmetics (AREA)
AT03786896T 2002-12-10 2003-12-08 Verwendung vom l-tartrat levalbuterolsalz in der herstellung eines dosierinhalators ATE324364T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43219502P 2002-12-10 2002-12-10

Publications (1)

Publication Number Publication Date
ATE324364T1 true ATE324364T1 (de) 2006-05-15

Family

ID=32507867

Family Applications (2)

Application Number Title Priority Date Filing Date
AT03786896T ATE324364T1 (de) 2002-12-10 2003-12-08 Verwendung vom l-tartrat levalbuterolsalz in der herstellung eines dosierinhalators
AT06110646T ATE498604T1 (de) 2002-12-10 2003-12-08 Aerosolformulierung umfassend levalbuterol l- tartratsalz

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT06110646T ATE498604T1 (de) 2002-12-10 2003-12-08 Aerosolformulierung umfassend levalbuterol l- tartratsalz

Country Status (19)

Country Link
US (8) US7256310B2 (cg-RX-API-DMAC7.html)
EP (3) EP1671942B2 (cg-RX-API-DMAC7.html)
JP (1) JP4570960B2 (cg-RX-API-DMAC7.html)
KR (3) KR20100080865A (cg-RX-API-DMAC7.html)
AT (2) ATE324364T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003295695B2 (cg-RX-API-DMAC7.html)
CA (1) CA2507572C (cg-RX-API-DMAC7.html)
CY (2) CY1106315T1 (cg-RX-API-DMAC7.html)
DE (2) DE60336089D1 (cg-RX-API-DMAC7.html)
DK (3) DK1572622T3 (cg-RX-API-DMAC7.html)
ES (3) ES2361172T5 (cg-RX-API-DMAC7.html)
IL (2) IL168739A (cg-RX-API-DMAC7.html)
MX (1) MXPA05006087A (cg-RX-API-DMAC7.html)
NO (1) NO331649B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ541168A (cg-RX-API-DMAC7.html)
PL (1) PL212725B1 (cg-RX-API-DMAC7.html)
PT (3) PT1671942E (cg-RX-API-DMAC7.html)
SI (2) SI1671942T2 (cg-RX-API-DMAC7.html)
WO (1) WO2004052835A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6466862B1 (en) * 1999-04-19 2002-10-15 Bruce DeKock System for providing traffic information
AU2005281511B2 (en) * 2004-09-09 2011-03-31 Cipla Limited Pharmaceutical composition comprising an isomer of a betamimetic agent and an anti-cholinergic agent
WO2006064283A1 (en) * 2004-12-17 2006-06-22 Cipla Limited Pharmaceutical compounds and compositions
US7579505B2 (en) 2004-12-17 2009-08-25 Cipla Limited Crystalline levosalbutamol sulphate and polymorphic forms thereof
US8542097B2 (en) 2011-04-13 2013-09-24 Jingle Technologies Llc Systems and methods for transmitting information, alerts, and/or comments to participants based on location information
EP3042892A1 (en) 2015-01-09 2016-07-13 Deva Holding Anonim Sirketi Amorphisation of levosalbutamol tartrate
CN106727318A (zh) * 2016-12-22 2017-05-31 山东京卫制药有限公司 一种气雾剂及其制备方法
WO2021188809A1 (en) * 2020-03-19 2021-09-23 Cai Gu Huang Inhalable formulation of a solution containing levalbuterol tartrate

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1200886A (en) 1966-09-23 1970-08-05 Allen & Hanburys Ltd Phenylaminoethanol derivatives
US5225183A (en) * 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
GB8828477D0 (en) † 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
US5766573A (en) 1988-12-06 1998-06-16 Riker Laboratories, Inc. Medicinal aerosol formulations
US5345980A (en) 1989-09-21 1994-09-13 Glaxo Group Limited Method and apparatus an aerosol container
US5362755A (en) 1990-01-05 1994-11-08 Sepracor, Inc. Method for treating asthma using optically pure (R)-albuterol
US5255183A (en) * 1990-05-29 1993-10-19 Interactive Voice Data System Inc. Telephone-based personnel tracking system
HUT67445A (en) * 1991-06-10 1995-04-28 Schering Corp Aerosol formulations containing 1,1,1,2-tetrafluorethane
EP0617610B1 (en) 1991-12-18 1997-03-19 Minnesota Mining And Manufacturing Company Suspension aerosol formulations
US5545745A (en) 1994-05-23 1996-08-13 Sepracor, Inc. Enantioselective preparation of optically pure albuterol
US5399765A (en) * 1994-05-23 1995-03-21 Sepracor, Inc. Enantioselective preparation of optically pure albuterol
SI0820279T1 (en) * 1995-04-14 2002-12-31 Smithkline Beecham Corporation Metered dose inhaler for albuterol
US5603918A (en) 1995-06-09 1997-02-18 Boehringer Ingelheim Pharmaceuticals, Inc. Aerosol composition of a salt of ipratropium and a salt of albuterol
US6040344A (en) 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
GB9806462D0 (en) 1998-03-26 1998-05-27 Glaxo Group Ltd Improved compositions for inhalation
ES2234266T3 (es) * 1998-07-24 2005-06-16 Jago Research Ag Formulaciones medicas para aerosoles.
CN1150890C (zh) * 1998-08-04 2004-05-26 杰格研究股份公司 药用气溶胶制剂
NZ511527A (en) * 1998-11-13 2002-10-25 Jago Res A Dry powder for inhalation
CN1173929C (zh) 1999-10-19 2004-11-03 中国科学院成都有机化学研究所 光学纯肾上腺素类β-激动剂的组合拆分制备法
US6451289B2 (en) 2000-03-24 2002-09-17 Sepracor Inc. Albuterol formulations
GB0030171D0 (en) 2000-12-11 2001-01-24 Cipla Ltd Process for preparing isomers of salbutamol
ES2292713T3 (es) * 2001-03-30 2008-03-16 Jagotec Ag Formulaciones medicinales en aerosol.
CN1206205C (zh) * 2001-04-26 2005-06-15 中国科学院成都有机化学研究所 R－沙丁胺醇酒石酸盐的制备方法
DE10120531A1 (de) * 2001-04-26 2002-10-31 Basf Ag Neue Reaktivfarbstoffe und deren Verwendung zum Färben von Substraten, welche nucleophile Gruppen enthalten

Also Published As

Publication number Publication date
CY1111330T1 (el) 2015-08-05
US7256310B2 (en) 2007-08-14
ES2361172T3 (es) 2011-06-14
PL212725B1 (pl) 2012-11-30
NO20053339L (no) 2005-09-07
CA2507572C (en) 2011-04-19
US20100272654A1 (en) 2010-10-28
CA2507572A1 (en) 2004-06-24
AU2003295695A1 (en) 2004-06-30
MXPA05006087A (es) 2005-09-30
US20080119564A1 (en) 2008-05-22
WO2004052835A1 (en) 2004-06-24
IL212369A0 (en) 2011-06-30
JP4570960B2 (ja) 2010-10-27
IL212369A (en) 2013-08-29
DE60336089D1 (de) 2011-03-31
JP2006509802A (ja) 2006-03-23
CY1106315T1 (el) 2011-10-12
DE60304900D1 (de) 2006-06-01
KR101166955B1 (ko) 2012-07-19
KR20080103614A (ko) 2008-11-27
DK1671942T3 (da) 2011-04-26
US20150071969A1 (en) 2015-03-12
ES2263051T3 (es) 2006-12-01
EP1572622A1 (en) 2005-09-14
KR20100080865A (ko) 2010-07-12
SI1671942T2 (sl) 2014-10-30
ATE498604T1 (de) 2011-03-15
US20180222845A1 (en) 2018-08-09
US8765153B2 (en) 2014-07-01
US20130236515A1 (en) 2013-09-12
AU2003295695B2 (en) 2009-08-20
DK1572622T3 (da) 2006-08-28
US20040115136A1 (en) 2004-06-17
ES2361172T5 (es) 2014-09-22
EP1671942B2 (en) 2014-07-23
EP2292584B1 (en) 2017-03-01
EP1572622B1 (en) 2006-04-26
KR20050088307A (ko) 2005-09-05
DK2292584T3 (en) 2017-05-01
EP1671942A1 (en) 2006-06-21
DE60304900T2 (de) 2006-10-19
PL377336A1 (pl) 2006-01-23
PT1671942E (pt) 2011-05-11
NZ541168A (en) 2008-10-31
PT1572622E (pt) 2006-08-31
PT2292584T (pt) 2017-06-12
NO20053339D0 (no) 2005-07-08
DK1671942T4 (da) 2014-09-22
ES2626648T3 (es) 2017-07-25
US20130028845A1 (en) 2013-01-31
IL168739A (en) 2011-06-30
SI1671942T1 (sl) 2011-04-29
NO331649B1 (no) 2012-02-13
US20160368858A1 (en) 2016-12-22
EP1671942B1 (en) 2011-02-16
EP2292584A1 (en) 2011-03-09
SI1572622T1 (sl) 2006-10-31

Similar Documents

Publication Publication Date Title
CY1115180T1 (el) Επιλογες θεραπειας για τη νοσο του fabry
DE602004029580D1 (de) Substituierte indolderivate für eine pharmazeutische zusammensetzung zur behandlung von atemwegserkrankungen
NO20085066L (no) 4,5-difenyl-pyrimidinyl-aminosubstituerte karboksylsyrer, fremgangsmate for deres fremstilling og anvendelse derav som medikamenter
DE502007006208D1 (de) Neue 1,4-benzothiepin-1,1-dioxidderivate mit verbesserten eigenschaften, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
NO20085064L (no) 4,5-difenyl-pyrimidinyl-oksy eller -merkaptosubstituerte karboksylsyrer, fremgangsmate for deres fremstilling og anvendelse derav som medikamenter
CY1117603T1 (el) Η λιξισενατιδη ως προσθετο στη μετφορμινη στην θεραπευτικη αγωγη του διαβητη τυπου 2
MX2008000255A (es) Activadores de urea glucocinasa.
DE112007001669A5 (de) Verwendung von Verbindungen der Formel A-R-X oder deren pharmazeutisch akzeptablen Salze zur Herstellung einer pharmazeutischen Zubereitung
UA83233C2 (ru) Замещенный 2-аминотетралин для лечения депрессии
ATE324364T1 (de) Verwendung vom l-tartrat levalbuterolsalz in der herstellung eines dosierinhalators
NO20082214L (no) 1,1-Diokso-tiomorfolinyl-indolyl-metanonderivater for anvendelse som H3-modulatorer
IL185410A0 (en) Use of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione in the treatment of parkinson's disease
ATE526967T1 (de) Medikamente für inhalationen enthaltend ein anticholinergikum und ein betamimetikum
WO2007020261A3 (de) Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel
ATE424195T1 (de) Verwendung von 2-amino-1,3-propandiolderivaten zur herstellung eines medikaments zur behandlung von bestimmten schmerzen
WO2009057528A1 (ja) 創薬のためのｐｅｔスクリーニング用分子プローブを製造するためのキット
DE602005000442D1 (de) Verwendung von alpha-1-Antitrypsin zur Herstellung eines Medikaments zur Behandlung von Fibromyalgie
DE602006018822D1 (de) Verwendung des Agomelatins zur Herstellung eines Medikamentes zur Behandlung der bipolaren Erkrankungen
DE60206391D1 (de) Verwendung von thiazolderivaten zur herstellung eines medikaments zur behandlung von chronischen obstruktiven atemwegserkrankungen
ATE523201T1 (de) Verwendung von salzsäure bei der herstellung eines medikaments zur behandlung von diabetes
ATE345124T1 (de) Verwendung von l-acetylcarnitin zur herstellung eines medikaments zur behandlung von anhedonia
RU2006110457A (ru) Средство для лечения сахарного диабета
DE602006004735D1 (de) Thiazolopyrimidine zur verwendung in der therapie
TH96064A (th) การใช้อนุพันธ์ของแนฟไทริดินในการผลิตเวชภัณฑ์สำหรับการบำบัดความดันสูงในปอด
AU2005907076A0 (en) A stand-alone mechanical counter that fits onto existing pressurised Metered Dose Inhalers(pMDIs) used to deliver medication to the lungs

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1572622

Country of ref document: EP